Incyte beats Q2 estimates by 55% and raises full-year guidance

Key Takeaways:

Incyte earned $3.09 a share in Q2, beating the $2.00 consensus by 55%
Revenue rose 38% to $1.67 billion, helped by a $246 million CMS settlement
Full-year sales guidance raised to as much as $5.26 billion from $4.94 billion

Incyte reported second-quarter earnings of $3.09 a share, beating the $2.00 consensus estimate by 55%, as revenue climbed 38% to $1.67 billion on strong drug sales and a one-time settlement with US regulators.

"The results reflect continued demand across our portfolio and the resolution of the CMS matter, which improves the economics of the Opzelura business," Chief Executive Officer Bill said on the earnings call. The company settled a lawsuit with the Centers for Medicare & Medicaid Services in June over Medicaid rebate criteria for Opzelura, its eczema and vitiligo treatment, adding $246 million in non-cash revenue during the quarter.

Total net product sales reached $1.49 billion, up 40% from a year earlier. Excluding the CMS settlement benefit, underlying net sales still grew 17%, driven by broad-based gains across every marketed product. Jakafi, Incyte's foundational blood-cancer drug, generated $817 million in sales, up 7% year over year. Opzelura contributed $450 million, including the settlement benefit. The hematology and oncology portfolio, including Niktimvo, Monjuvi and Zynyz, grew 69% to $222 million.

Incyte raised its full-year 2026 net sales guidance to a range of $5.13 billion to $5.26 billion, up from a prior forecast of $4.77 billion to $4.94 billion. The company also lifted Opzelura guidance to $1.05 billion to $1.10 billion, reflecting the CMS settlement's estimated $300 million to $310 million impact. Shares rose 0.11% in premarket trading to $119, near the 52-week high of $120.71.

The quarter included several pipeline milestones. Jakafi XR, the extended-release formulation, generated $10 million in sales during its initial launch quarter, with management targeting $40 million to $50 million for the full year. The company also discontinued development of INCB160058, a blood-cancer drug, after what it described as formulation challenges and an insufficient profile. Chief Development Officer Pablo said Incyte expects a catalyst-rich second half, including European approval of Opzelura for moderate atopic dermatitis, data from registrational trials in hidradenitis suppurativa and prurigo nodularis, and 10 pipeline data readouts.

The guidance raise signals management expects demand to remain strong across the portfolio. Investors will watch the Jakafi XR conversion rate and the European Opzelura launch in the third quarter as key catalysts for the remainder of the year.

This article is for informational purposes only and does not constitute investment advice.